risedronate

risedronate. It is a nitrogen-containing bisphosphonate medication primarily used to treat and prevent osteoporosis in postmenopausal women and men, and to treat Paget's disease of bone. The drug works by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. It is marketed under brand names including Actonel and Atelvia by companies such as Procter & Gamble and Sanofi.

Medical uses

The primary medical use is for the treatment and prevention of postmenopausal osteoporosis, significantly reducing the incidence of vertebral and non-vertebral fractures. It is also approved for the treatment of glucocorticoid-induced osteoporosis in men and women and for the management of Paget's disease of bone, where it works to normalize excessive bone turnover. Clinical trials, such as the HIP study and the VERT study, have demonstrated its efficacy in these populations. The medication is sometimes used off-label in the management of other metabolic bone diseases, including osteogenesis imperfecta.

Adverse effects

Common adverse effects include gastrointestinal disturbances such as dyspepsia, abdominal pain, and esophagitis, which are typical of the bisphosphonate class. More serious but rare risks include osteonecrosis of the jaw, particularly associated with invasive dental procedures, and atypical femoral fractures with long-term use. Other reported effects include musculoskeletal pain, headache, and a potential increased risk of atrial fibrillation, as noted in analyses by the Food and Drug Administration. Severe hypocalcemia is a risk, especially in patients with underlying conditions like hypoparathyroidism.

Pharmacology

As a potent third-generation bisphosphonate, it acts by binding to hydroxyapatite crystals in bone, where it is internalized by osteoclasts during bone resorption. Inside the osteoclast, it inhibits the mevalonate pathway by blocking the enzyme farnesyl pyrophosphate synthase, disrupting the prenylation of proteins like GTPase and leading to osteoclast apoptosis. It is poorly absorbed orally, with bioavailability reduced by food, calcium, and antacids. The drug is not metabolized and is excreted unchanged by the kidney via glomerular filtration and tubular secretion.

History

The compound was developed in the late 1980s by the pharmaceutical company Procter & Gamble through their Norwich Eaton division. It received its first approval from the Food and Drug Administration in 1998 for the treatment of Paget's disease of bone. Subsequent approvals for osteoporosis followed, with the weekly formulation of Actonel gaining approval in 2000. The development of a delayed-release formulation, Atelvia, which could be taken after breakfast, was approved in 2010 following clinical trials presented to the European Medicines Agency.

Society and culture

It is available as a generic medication in many countries following the expiration of key patents held by Procter & Gamble and its partner Alliance Pharmaceuticals. The drug has been the subject of extensive direct-to-consumer advertising campaigns in the United States and was involved in litigation regarding alleged patent infringement with other pharmaceutical firms like Teva Pharmaceutical Industries. Its role in osteoporosis management has been analyzed in major treatment guidelines from organizations like the National Osteoporosis Foundation and the American Association of Clinical Endocrinologists.

Category:Drugs